Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab-IRDye 800CW
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab-IRDye 800CW is an immunoconjugate composed of the recombinant chimeric monoclonal antibody cetuximab covalently linked to the near-infrared fluorescent dye IRDye 800CW via an N-hydroxysuccinimide (NHS) ester linkage. Cetuximab targets and binds specifically to the extracellular domain of the epidermal growth factor receptor (EGFR), which is overexpressed in various tumor types. The conjugation with IRDye 800CW enables real-time intraoperative fluorescence imaging for tumor visualization and surgical navigation. This agent is primarily being developed as an optical imaging agent to aid in identifying tumor margins during surgery, particularly in head and neck squamous cell carcinoma and malignant glioma[1][4][5][6][8]. The mechanism of action involves both EGFR binding for tumor targeting and fluorescence emission from IRDye 800CW for image-guided surgery.
- Brand names
- cetuximab-IRDye 800CWcetuximab-IRDye800CWcetuximab-IRDye-800CW
- Other names
- Cet-IRDye800Cet-IRDye-800Cet-IRDye 800cetuximab-IRDye800CWcetuximab-IRDye-800CWcetuximab-IRDye 800CW
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on cetuximab-IRDye 800CW.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab-IRDye 800CW.